课题基金 / 基金详情

CYTOKINE SIGNALING IN RENAL FIBROSIS

CYTOKINE SIGNALING IN RENAL FIBROSIS
肾纤维化中的细胞因子信号传导
批准号:
6381574
负责人:
Erwin P. Bottinger
金额:
$31.25万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-07-15 至 2004-06-30

项目摘要

项目成果

Erwin P. Bottinger的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Adapted from Investigator's Abstract): This is a new application by a new investigator with the long-term objectives to study intracellular networks of cytokine signaling which mediate renal fibrogenesis, a major process in the pathogenesis of end stage renal disease. The overall hypothesis is that members of the Smad family of intracellular proteins integrate opposing pro-fibrogenic and anti-fibrogenic signaling pathways into signaling thresholds that regulate fibrogenesis. This hypothesis will be tested by studying the function, downstream targets and regulation of the positive mediator Smad2, and the putative negative regulator Smad7, in the opposing signaling pathways of pro-fibrogenic TGFbeta and anti-fibrogenic TNFalpha. Preliminary studies indicate that Smad2 and Smad7 are promising candidate signaling molecules in renal fibrogenesis, with opposite activities. The first Specific aim will test the hypothesis that Smad2 promotes fibrosis by activation of fibrogenic genes in response to TGFbeta. The effects of Smad2 deficiency in Smad2 null mouse embryonic fibroblasts on the expression of selected genes encoding matrix proteins, and on fibroblast proliferation will be determined. The second Specific Aim will test the hypothesis that Smad2 function as a positive regulator and Smad7 functions as a negative regulator of an overlapping pool of fibrogenic genes. To do this the PI will identify and compare gene pools which are differentially-regulated in wild type mouse embryonic fibroblasts (MEFwt), Smad2 null MEFs (MEF2-/-) and MEFs with constitutive over expression of Smad7 (MEF7+), using high-throughput microarray methods for comparative analysis of gene expression. Genes with reduced expression in both MEF2-/- and MEF7+ cells relative to MEFwt cells will be identified and characterized. The third Specific Aim will test whether Smad7 functions by inhibition of Smad2 activation, or transcriptional repression of Smad2-activated target gene promoters, or both. The last Specific Aim will examine whether TGFbeta and TNFalpha signaling pathways converge to regulate transcription of Smad7. To do this, the PI has cloned the functional human Smad7 promoter region. Promoter deletion analyses and electrophoretic mobility shift assays (EMSAs) will be utilized to identify the functional cis-acting elements in the Smad7 gene and their cognate transcription factors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Genomic Medicine Pilot For Hypertension And Kidney Disease In Primary Care
Genomic Medicine Pilot For Hypertension And Kidney Disease In Primary Care
Genomic Medicine Pilot For Hypertension And Kidney Disease In Primary Care
Glomerular Cell-Cell Crosstalk and Injury
海外基金